Study On Prognostic Role Of Low Platelet Count In Preeclampsia And Eclampsia

e13549 Background: Hematologic markers of inflammation have been shown to be prognostic in different malignancies. Also in glioblastoma multiforme (GBM) a prognostic role has been demonstrated. The purpose of this study is to evaluate retrospectively the prognostic role of these markers in patients receiving a concomitant radio-chemotherapy after surgery. Methods: Sixty-five GBM patients have been treated with concomitant radio-chemotherapy after surgery at our institute from 2008 to 2017. Information on blood counts were carried out the day before starting therapy and after the day before the last cycle of chemotherapy. Neutrophil/lymphocyte ratio (NLR) and Platelet/lymphocyte ratio (PLR) were computed as the ratio of the absolute neutrophil count and absolute platelet count by the absolute lymphocyte count respectively. Systemic Inflammatory Index (SII) was calculated as platelet count × neutrophil count/lymphocyte count. The optimal cut-point was obtained using X-tile software version 3.6.1. Results: NLR and PLR baseline value didn’t show a statistic a statistically significant prognostic role in PFS or OS. Patients with baseline SII < 480 showed both better PFS and OS (OS: 22.1 VS 11.8 mo p-values 0.0516; PFS: 10.6 VS 5.7 mo p-values 0.0351). Patients aged < 60 years showed better PFS and OS. (PFS 10.3 VS 5.5 p-values 0.0501; OS: 20.6 VS 11.2 mo p-values 0.0124). Statistical significance for SII and age was maintained for both PFS and OS in multivariate analysis as shown in Table 1. Baseline values of NLR PLR and SII have also been correlated with the best response and ORR without showing statistical significance. Conclusions: This restorative study confirms the prognostic value of inflammatory indices in patients with GBM. Correlation analysis with the methylation status of MGMT is ongoing.[Table: see text][Table: see text]

Download Full-text

Prognostic Role of Mean Platelet Volume and Platelet Count in Ischemic and Hemorrhagic Stroke

Journal of Stroke and Cerebrovascular Diseases ◽

10.1016/j.jstrokecerebrovasdis.2009.03.003 ◽

2010 ◽

Vol 19 (1) ◽

pp. 66-72 ◽

Cited By ~ 63

Author(s):

Füsun Mayda-Domaç ◽

Handan Mısırlı ◽

Mustafa Yılmaz

Keyword(s):

Platelet Count ◽

Mean Platelet Volume ◽

Hemorrhagic Stroke ◽

Prognostic Role ◽

Platelet Volume

Download Full-text

Clinical impact of glycans in platelet and megakaryocyte biology

Blood ◽

10.1182/blood.2020009303 ◽

2022 ◽

Author(s):

Leonardo Rivadeneyra ◽

Hervé Falet ◽

Karin Hoffmeister

Keyword(s):

Platelet Count ◽

Blood Circulation ◽

Thrombus Formation ◽

Clinical Impact ◽

Risk Of Bleeding ◽

Clinical Observations ◽

Low Platelet Count ◽

High Platelet Count ◽

Human And Mouse

Humans produce and remove 1011 platelets daily to maintain a steady-state platelet count. The production of platelets by bone marrow megakaryocytes and their removal from the blood circulation are tightly regulated mechanisms, and abnormalities in both processes can result in thrombocytopenia (low platelet count) or thrombocytosis (high platelet count), often associated with the risk of bleeding or overt thrombus formation, respectively. This review focuses on the role of glycans, also known as carbohydrates or oligosaccharides, including N- and O-glycans, proteoglycans, and glycosaminoglycans, in human and mouse platelet and megakaryocyte physiology. Based on recent clinical observations and mouse models, we focused on the pathological aspects of glycan biosynthesis and degradation and its effects on platelet numbers and megakaryocyte function.

Download Full-text